KCM
ACAD icon

Kingdon Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Kingdon Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-45,000
Closed -$817K – 178
2013
Q2 		$817K Buy
+45,000
New +$620K 0.05% 188

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Kingdon Capital Management's ACAD Position: Q3 2013 in Review

Kingdon Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2013, closing a stake of 45,000 shares — an estimated $817K sold.

Kingdon Capital Management first reported a position in ACAD in Q2 2013 and held it in 1 quarter. The position peaked at $817K in Q2 2013. 142 funds tracked by Wall St. Rank hold ACAD as of Q3 2013.

  • Kingdon Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Kingdon Capital Management sold 45,000 Acadia Pharmaceuticals shares in Q3 2013, an estimated $817K.
  • Kingdon Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Kingdon Capital Management's Acadia Pharmaceuticals position peaked at $817K in Q2 2013.
  • 142 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2013.

Based on Kingdon Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.